Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer

por Skov, Natascha, Alves, Carla L., Ehmsen, Sidse, Ditzel, Henrik J.
Publicado 2022

Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer

por Ehmsen, Sidse, Asmussen, Anders, Jeppesen, Stefan S., Nilsson, Anna Christine, Kragh, Amalie, Frederiksen, Henrik, Ditzel, Henrik J.
Publicado 2022

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

por Ehmsen, Sidse, Asmussen, Anders, Jeppesen, Stefan S., Nilsson, Anna Christine, Østerlev, Sabina, Kragh, Amalie, Frederiksen, Henrik, Ditzel, Henrik J.
Publicado 2022

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer

por Kodahl, Annette R., Ehmsen, Sidse, Pallisgaard, Niels, Jylling, Anne M. B., Jensen, Jeanette D., Lænkholm, Anne‐Vibeke, Knoop, Ann S., Ditzel, Henrik J.
Publicado 2018

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

por Ehmsen, Sidse, Asmussen, Anders, Jeppesen, Stefan S., Nilsson, Anna Christine, Østerlev, Sabina, Vestergaard, Hanne, Justesen, Ulrik S., Johansen, Isik S., Frederiksen, Henrik, Ditzel, Henrik J.
Publicado 2021

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

por Karimi, Leena, Alves, Carla L., Terp, Mikkel G., Tuttolomondo, Martina, Portman, Neil, Ehmsen, Sidse, Johansen, Lene E., Bak, Martin, Lim, Elgene, Ditzel, Henrik J.
Publicado 2023

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

por Al-Qasem, Abeer J., Alves, Carla L., Ehmsen, Sidse, Tuttolomondo, Martina, Terp, Mikkel G., Johansen, Lene E., Vever, Henriette, Hoeg, Luna V. A., Elias, Daniel, Bak, Martin, Ditzel, Henrik J.
Publicado 2022

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

por Ehmsen, Sidse, Pedersen, Rune M., Bang, Line L., Asmussen, Anders, Kragh, Amalie, Holm, Dorte K., Sydenham, Thomas V., Jensen, Thøger G., Jeppesen, Stefan S., Frederiksen, Henrik, Andersen, Thomas E., Ditzel, Henrik J.
Publicado 2023

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

por Bao, Yi, Oguz, Gokce, Lee, Wee Chyan, Lee, Puay Leng, Ghosh, Kakaly, Li, Jiayao, Wang, Panpan, Lobie, Peter E., Ehmsen, Sidse, Ditzel, Henrik J., Wong, Andrea, Tan, Ern Yu, Lee, Soo Chin, Yu, Qiang
Publicado 2020

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

por Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J.
Publicado 2021

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

por Alves, Carla L., Ehmsen, Sidse, Terp, Mikkel G., Portman, Neil, Tuttolomondo, Martina, Gammelgaard, Odd L., Hundebøl, Monique F., Kaminska, Kamila, Johansen, Lene E., Bak, Martin, Honeth, Gabriella, Bosch, Ana, Lim, Elgene, Ditzel, Henrik J.
Publicado 2021

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

por Kaminska, Kamila, Akrap, Nina, Staaf, Johan, Alves, Carla L., Ehinger, Anna, Ebbesson, Anna, Hedenfalk, Ingrid, Beumers, Lukas, Veerla, Srinivas, Harbst, Katja, Ehmsen, Sidse, Borgquist, Signe, Borg, Åke, Pérez-Fidalgo, Alejandro, Ditzel, Henrik J., Bosch, Ana, Honeth, Gabriella
Publicado 2021

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

por Ma, Shijun, Zhao, Yue, Lee, Wee Chyan, Ong, Li-Teng, Lee, Puay Leng, Jiang, Zemin, Oguz, Gokce, Niu, Zhitong, Liu, Min, Goh, Jian Yuan, Wang, Wenyu, Bustos, Matias A., Ehmsen, Sidse, Ramasamy, Adaikalavan, Hoon, Dave S. B., Ditzel, Henrik J., Tan, Ern Yu, Chen, Qingfeng, Yu, Qiang
Publicado 2022